Response and follow-up
| Patient no. . | Response day 30 . | PFS, mo . | Status at last F/U . | Survival, mo . |
|---|---|---|---|---|
| 1 | VGPR | 15+ | CR | 15+ |
| 2 | PR | 15+ | CR | 15+ |
| 5 | VGPR | 12+ | VGPR* | 12+ |
| 6 | PR | 10+ | CR | 10+ |
| 7 | VGPR | 8+ | CR | 8+ |
| 8 | PR | 3+ | CR | 3+ |
| 9 | PR | 8+ | CR | 8+ |
| 10 | VGPR | 4+ | CR | 4+ |
| 11 | VGPR | 5+ | VGPR† | 5+ |
| 13 | PR | 2+ | PR‡ | 2+ |
| Patient no. . | Response day 30 . | PFS, mo . | Status at last F/U . | Survival, mo . |
|---|---|---|---|---|
| 1 | VGPR | 15+ | CR | 15+ |
| 2 | PR | 15+ | CR | 15+ |
| 5 | VGPR | 12+ | VGPR* | 12+ |
| 6 | PR | 10+ | CR | 10+ |
| 7 | VGPR | 8+ | CR | 8+ |
| 8 | PR | 3+ | CR | 3+ |
| 9 | PR | 8+ | CR | 8+ |
| 10 | VGPR | 4+ | CR | 4+ |
| 11 | VGPR | 5+ | VGPR† | 5+ |
| 13 | PR | 2+ | PR‡ | 2+ |
All patients were alive at end of study; no patient had relapse/progression.
CR indicates complete remission; PR, partial response; VGPR, very good partial response; PFS, progression-free survival; and F/U, follow-up.
Eight percent atypical lymphocytes on peripheral blood smear.
Six percent atypical lymphocytes on peripheral blood smear.
Lymphocytosis decreased from 185 000 to 6400.